Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Department of Medicine, Renaissance School of Medicine at Stony Brook University, NY, USA.
Expert Rev Med Devices. 2021 Jun;18(6):499-504. doi: 10.1080/17434440.2021.1926984. Epub 2021 May 31.
: Despite significant advances in diabetes care over the last three decades, the majority of people living with T1D are not meeting established metabolic goals. Automated insulin delivery can help achieve these metabolic goals (HbA1c and TIR).: This review examines the new features and available data regarding safety and efficacy of the MiniMed™ 780 G, a second-generation advanced hybrid closed-loop system. Reported outcomes include time in, above and below range, HbA1c, diabetic ketoacidosis and severe hypoglycemia.: The initial pivotal trials of the MiniMed™ 780 G have demonstrated promising clinical and safety outcomes. Real-world data and longer-term studies are still needed. The success of AID devices moving forward hinges on their ease of use and ability to reduce and relieve the burden of living with T1D.
尽管在过去的三十年中糖尿病护理取得了重大进展，但大多数 T1D 患者仍未达到既定的代谢目标。自动胰岛素输送可以帮助实现这些代谢目标（HbA1c 和 TIR）。本文回顾了第二代高级混合闭环系统 MiniMed™ 780G 的新功能和安全性、有效性相关的可用数据。报告的结果包括时间在、高于和低于范围、HbA1c、糖尿病酮症酸中毒和严重低血糖。MiniMed™ 780G 的初步关键试验已经显示出有希望的临床和安全结果。仍需要真实世界的数据和更长期的研究。AID 设备的成功取决于其易用性以及减轻 T1D 患者负担的能力。
